Elanco Animal Health, 2500 Innovation Way, Greenfield, IN, 46140, USA.
Elanco Australasia Pty Ltd, 245 Western Road, Kemps Creek, NSW, 2178, Australia.
Parasit Vectors. 2021 Mar 5;14(1):139. doi: 10.1186/s13071-021-04660-2.
Credelio™ (lotilaner; Elanco) is indicated for the treatment of flea and tick infestations on cats at a recommended lotilaner dose rate of 6-24 mg/kg. This study evaluated the efficacy and safety of lotilaner following a single oral administration to cats for the treatment and prevention of adult Ctenocephalides felis fleas and flea egg production under laboratory conditions.
Two treatment groups of ten cats each were used in this study. One group was treated with lotilaner at a dose rate of 6-9 mg/kg on Day 0 and the other group served as the control group. Each cat was infested with 100 unfed adult fleas on days -1, 6, 13, 20 and 29. At 24 h post-treatment or post-infestation, each cat was combed to remove and count adult live fleas. At each time point, flea eggs were also collected and counted from under each cat cage.
Following a single oral administration of lotilaner at a minimum dose rate of 6 mg/kg (range 6.00-8.57 mg/kg), the lotilaner group displayed 100%, 100%, 99.9%, 99.9% and 99.8% efficacy against adult live flea counts as compared to the control group on Days 1, 7, 14, 21 and 30, respectively. At each time point, adult flea counts from the lotilaner-treated cats were significantly lower (P < 0.0001) than from the control group. A mean flea egg count of 22.6 in the lotilaner-treated cats (compared to 441.7 in the control animals) was observed 24 h post-treatment. No eggs were present from any of the treated cats on Days 7, 14 and 30 and a single egg was detected on a single treated cat on Day 21. One adverse event (regurgitated food) was observed during the study in one treated cat approximately 1 h after dosing.
Lotilaner was well tolerated; only one adverse event was observed in the treated group. Virtually all adult fleas were killed within 24 h post-treatment or post-infestation in cats treated with a single dose of lotilaner as compared to the control group, thus significantly reducing the number of flea eggs being produced for 30 days after treatment.
Credelio™（洛特兰纳；礼蓝）被批准用于治疗猫的跳蚤和蜱虫感染，推荐剂量为 6-24 毫克/千克。本研究在实验室条件下，评估了单剂量口服洛特兰纳治疗和预防成年猫栉头蚤成虫和跳蚤卵产生的效果和安全性。
本研究使用了两组各 10 只猫。一组以 6-9 毫克/千克的剂量在第 0 天接受洛特兰纳治疗，另一组作为对照组。每只猫在第-1、6、13、20 和 29 天被 100 只未进食的成年跳蚤感染。在治疗后或感染后 24 小时，每只猫都被梳理以去除并计数成虫活跳蚤。在每个时间点，也从每只猫笼下收集并计数跳蚤卵。
在最低剂量为 6 毫克/千克（范围 6.00-8.57 毫克/千克）的单剂量口服洛特兰纳后，洛特兰纳组在第 1、7、14、21 和 30 天与对照组相比，对成年活跳蚤计数的疗效分别为 100%、100%、99.9%、99.9%和 99.8%。在每个时间点，洛特兰纳治疗猫的成虫跳蚤计数均显著低于对照组（P<0.0001）。在治疗后 24 小时，洛特兰纳治疗猫的平均跳蚤卵数为 22.6（与对照组的 441.7 相比）。在第 7、14 和 30 天，任何治疗猫都没有卵，在第 21 天，一只治疗猫仅检测到一个卵。在治疗组中观察到 1 只猫在给药后约 1 小时出现 1 次不良事件（呕吐食物）。
洛特兰纳耐受良好；仅在治疗组观察到 1 起不良事件。与对照组相比，在单剂量洛特兰纳治疗的猫中，几乎所有成年跳蚤在治疗后 24 小时内或感染后被杀死，从而在治疗后 30 天内显著减少跳蚤卵的产生数量。
